Fluorescent ligand for human progesterone receptor imaging in live cells. by Weinstain, Roy et al.
UC San Diego
UC San Diego Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
Fluorescent Ligand for Human Progesterone Receptor Imaging in
Live Cells
Roy Weinstain,† Joan Kanter,† Beth Friedman,† Lesley G. Ellies,∥ Michael E. Baker,‡
and Roger Y. Tsien*,†,§
†Department of Pharmacology 0647, ∥Department of Pathology 0063, ‡Department of Medicine 0693, and §Howard Hughes Medical
Institute (HHMI),University of California, San Diego, La Jolla, California 92093, United States
*S Supporting Information
ABSTRACT: We employed molecular modeling to design and then
synthesize fluorescent ligands for the human progesterone receptor. Boron
dipyrromethene (BODIPY) or tetramethylrhodamine were conjugated to
the progesterone receptor antagonist RU486 (Mifepristone) through an
extended hydrophilic linker. The fluorescent ligands demonstrated
comparable bioactivity to the parent antagonist in live cells and triggered
nuclear translocation of the receptor in a specific manner. The BODIPY
labeled ligand was applied to investigate the dependency of progesterone
receptor nuclear translocation on partner proteins and to show that
functional heat shock protein 90 but not immunophilin FKBP52 activity is
essential. A tissue distribution study indicated that the fluorescent ligand
preferentially accumulates in tissues that express high levels of the receptor
in vivo. The design and properties of the BODIPY-labeled RU486 make it a
potential candidate for in vivo imaging of PR by positron emission tomography through incorporation of 18F into the BODIPY
core.
The progesterone receptor (PR) is a ligand-activatedsteroid receptor that belongs to the nuclear receptor
superfamily of transcription factors.1,2 PR is expressed at low
levels in most physiological systems but peaks in the female
reproductive system and in the central nervous system.3 Thus,
it plays a central role in reproductive events and sexual
behavior. PR dysfunction has been indicated in multiple
disorders including reproductive conditions,4 neurological
syndromes,5 and cancer (breast,6 ovarian,7 endometrial8). As
such, considerable effort has been focused on understanding PR
functions and their underlying mechanisms in normal and
pathological conditions. The human PR is encoded by a single
gene that is expressed as two isoforms, PR-A and PR-B, which
share most of the functional elements but have distinct
functions. While PR-A remains predominantly in the nucleus,
PR-B resides mostly in the cytosol as part of a multiprotein
complex, which modulates its activity. According to current
understanding, upon ligand binding PR-B dissociates from at
least part of the complex, dimerizes, and translocates to the
nucleus, where it recruits coregulating proteins and binds
specific DNA sequences to exert its transcriptional effect.
Recently, fusions of fluorescent protein tags to PR and its
regulators have enabled their imaging with high spatial and
temporal resolution, significantly improving understanding of
dynamic processes such as localization, cell cycle dependence,
and recycling.9−11 However, this approach requires genetic
manipulation, expression of non-native PR, and often the use of
cells that do not express PR endogenously. Complementary to
receptor labeling, fluorescent ligands offer advantages such as
receptor imaging in endogenously expressing cells, quantifica-
tion of ligand−receptor interactions, and measurement of
receptor−ligand complex diffusion rates.12 While biologically
functional fluorescent ligands for many G protein-coupled
receptors,13 retinoic acid receptor,14 and estrogen receptor15
have been reported, efforts to develop fluorescent ligands for
PR were either unsuccessful16 or have not been applied to
receptor imaging.17,18 The only functional fluorescent PR-
ligand in mammalian cells was reported almost a decade ago,
when fluorescein labeled RU486 (Mifepristone), a PR
antagonist, was demonstrated to concentrate in the nuclei of
PR expressing cells.19 However, it required prolonged
incubation time and cells had to be fixed prior to imaging.
Recently, an elegant procedure for fluorine displacement in
boron-dipyrromethene (BODIPY) dyes has been described20
which was later used to introduce a 18F radioisotope into a
BODIPY scaffold to generate a dual fluorescence/positron
emission tomography (PET) imaging reagent.21 Other
chemistries for rapid incorporation of a PET isotope into a
strong fluorophore exist, e.g., a near-infrared-absorbing cyanine
dye with a pendant fluoborate,22 but the size of that dye and its
polar substituents would probably prevent membrane per-
meation. With this in mind, we sought to develop a PR
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fluorescent ligand based on a BODIPY dye that could be used
for fluorescent imaging of PR in vitro and potentially be
translated into a PET tracer for PR imaging in vivo, without
modifying the original structure.
RU486 is a synthetic 19-nor steroid that acts as a competitive
antagonist to PR (Figure 1). It has high affinity for PR (∼5
times lower Kd compared to the natural agonist progester-
one23), and upon binding to PR, it preserves many of the
processes initiated by progesterone binding, i.e., dissociation of
PR from the multiprotein complex, dimerization, translocation
to the nucleus, and DNA binding. The main functional
difference is the inability of the receptor to recruit coactivators
required for transcriptional activation when bound to RU486.24
These attributes make RU486 an attractive PR ligand for
fluorescence labeling. Additionally, RU486 can tolerate various
modifications of the dimethylamino group without significantly
compromising its binding affinity and biological activity.25 This
property has been recently exploited to develop an RU486-
based MRI contrast agent.26 Therefore, we designed a
BODIPY-labeled RU486, where the dye is separated from the
ligand by a linker, intended to decrease both steric hindrance
from the bulky dye as well as hydrophobicity of the conjugate
(RU486-BODIPY, Figure 1a). For labeling, we chose a
BODIPY structure that was demonstrated to be amenable to
18F introduction.21 Molecular docking of BODIPY-labeled
RU486 with human PR showed that the labeled ligand is
oriented similarly to unlabeled RU486 inside the binding
pocket and that the linker extends outward through the binding
pocket access channel (Figure 1b). Important contacts between
the ligand and key amino acids are maintained for the labeled
ligand (SI Figure S1). The model also predicted that the linker
is sufficiently long (16 atoms from the aniline nitrogen to the
BODIPY attachment point) to place the bulky BODIPY well
outside the protein, minimizing its steric hindrance (Figure 1c).
To test whether this labeling strategy might be extended to
other dyes and bulky groups, we labeled RU486 with 5-
carboxytetramethylrhodamine (RU486-TAMRA, Figure 1a) in
a similar design. The conjugates were prepared by first oxidative
N-demethylation of RU486, followed by alkylation with 6-
bromohexanoic acid. Then, N-Boc-2,2′-(ethylenedioxy)-
diethylamine was conjugated to the carboxylic acid, followed
by TFA-mediated Boc-deprotection and conjugation to the
respective dye (6% and 7% overall yields for RU486-BODIPY
and RU486-TAMRA, respectively; SI Scheme S1).
The antagonistic activity of the ligands was assessed by their
ability to inhibit progesterone-induced increase in alkaline
phosphatase activity in intact T47D cells.27 T47D are human
hormone-dependent epithelial cells isolated from ductal
carcinoma of the breast, which naturally express high level of
PR. While the potency of RU486-TAMRA was ∼5-fold lower
than RU486, that of RU486-BODIPY was ∼1.5-fold higher
(Table 1 and SI Figure S2). The difference in potency between
the two fluorescent ligands might arise from their distinct
hydrophobic/hydrophilic nature (Table 1). The higher polarity
of RU486-TAMRA could hinder its membrane permeability,
leading to lower intracellular effective concentration. Con-
versely, the BODIPY dye could be engaged in additional
hydrophobic interactions with the receptor, slightly increasing
its affinity. The labeled ligands showed spectroscopic properties
characteristic of their respective dyes (Table 1 and SI Figure
S3a,b). Interestingly, the quantum yield of both compounds
increased in a dose-dependent manner when bovine serum
albumin (BSA) was added to the measurement buffer (0.04 up
to 0.29 and 0.04 up to 0.08 for RU486-BODIPY and RU486-
TAMRA, respectively; SI Figure S3c), suggesting that the
ligand’s brightness might also increase when bound to the
receptor. Based on this BSA-dependent increase in quantum
yield, the binding constants of the ligands to BSA were
measured to be K = 6349 ± 544 and 31 348 ± 2063 M−1
(RU486-BPDIPY and RU486-TAMRA, respectively; SI Figure
Figure 1. Fluorescent ligands of progesterone receptor. (a) Chemical
structures of RU486 and its fluorescently labeled derivatives RU486-
BODIPY and RU486-TAMRA. Molecular modeling of RU486-
BODIPY (green) bound to human PR showing (b) orientation inside
the ligand binding pocket compared to RU486 (orange) (amino acids
712−720 have been removed for clarity) and (c) the linker extends
out of the binding pocket, placing the BODIPY dye well outside the
protein shell.
Table 1. Antagonistic and Spectroscopic Properties of RU486 and Its Fluorescent Derivatives
IC50
a RBAb log Pc λex
d λem
d Φfl
RU486 1.70 ± 0.24 1 (4.72)
RU486-BODIPY 1.10 ± 0.22 1.5 3.51 ± 0.24 495 505 0.04−0.29
RU486-TAMRA 7.55 ± 1.34 0.2 0.95 ± 0.14 550 578 0.04−0.08
aDetermined from dose−response curve of progesterone-induced alkaline phosphatase activity inhibition. Units are in nM. bRelative biological
activity as determined by ratio of IC50(RU486) to IC50 of tested compound.
cMeasured using shake flask method. In parentheses: from DrugBank
[DB00834]. dUnits are in nm.
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S3d). Taken together, these results show that RU486-BODIPY
and RU486-TAMRA can bind PR as high affinity antagonists
with spectroscopic properties suitable for fluorescence imaging.
Next, we evaluated the fluorescent ligands for imaging
endogenously expressed PR in live cells. In T47D cells
incubated with 5 nM RU486-BODIPY, fluorescence was almost
entirely confined to the nuclei and excluded from the nucleoli
(Figure 2a). Low levels of fluorescence were also detectable in
the cytoplasm. Interestingly, the nuclear distribution of the
fluorescent ligand was retained even 24 h after a brief
incubation (SI Figure S4). This nuclear accumulation can be
reversed by applying unlabeled RU486 (SI Figure 5), thus
representing specific binding, whose persistence may be a result
of the inhibitory effect of antagonist binding on PR
processing.28 Staining with anti-human PR antibody revealed
colocalization of RU486-BODIPY and PR, along with a positive
correlation between the fluorescent ligand accumulation level
and the antibody labeling intensity (SI Figure S6). Incubation
with increasing concentrations of RU486-BODIPY revealed
that above 5 nM, nonspecific accumulation starts to appear,
eventually surpassing the nuclear signal (SI Figure S7). When
MDA-MB-231, an epithelial breast cancer cell line that does not
express PR, was similarly treated with RU486-BODIPY,
fluorescence was completely excluded from the nuclei but
was observed in the cytoplasm (Figure 2a). The cytoplasmic
retention of RU486-BODIPY in the absence of its target
binding site (i.e., PR) represents nonspecific binding which is
probably a result of the molecule’s hydrophobicity (log P =
3.5). Another possible consequence of the hydrophobicity of
RU486-BODIPY is the extended time required for PR nuclear
translocation process to complete (∼1 h). Antiprogestins, such
as RU486, have been found to bind to both the PR and the
glucocorticoid receptor (GR) with high affinity. We therefore
tested the specificity of RU486-BODIPY nuclear accumulation
in T47D cells by competing it with 20-fold excess of either
progesterone (PR selective) or dexamethasone (GR selective).
While excess progesterone completely inhibited accumulation
of fluorescence in the nuclei, dexamethasone had no observable
effect (Figure 2b), demonstrating the specificity of the
fluorescent ligand to PR in this experimental setting. In
addition, this result establishes that RU486-BODIPY binds PR
through the ligand binding domain (LBD) and not through
allosteric sites.
RU486-TAMRA showed similar accumulation patterns as
RU486-BODIPY, concentrating in the nuclei of T47D cells but
not in MDA-MB-231 cells. Nuclear localization was similarly
specific to PR and persisted for at least 24 h (SI Figure S8a−c).
In contrast to RU486-BODIPY’s tendency to accumulate in
membranes in the absence of PR, RU486-TAMRA was easily
washed out, maintaining a high ratio of nuclear-to-cytosol
fluorescence even at high concentrations (SI Figure S9),
probably due to its higher hydrophilicity. In addition, it
accumulated in the nucleus at a much faster rate than RU486-
BODIPY (∼18 min, SI Figure S10). However, a higher
concentration was required to observe its effect (SI Figure S9).
Altogether, these results demonstrate that the fluorescent
ligands specifically bind human PR in T47D cells, causing PR to
translocate to the nucleus and slow down the receptor’s
recycling process, thus mimicking the biological effects of
unlabeled RU486.
After establishing that the fluorescent ligands retain many of
the biological properties of RU486, we applied RU486-
BODIPY to study the dependency of PR nuclear translocation
process on proteins involved in its complex. In vitro assembly
studies established the identity of the proteins required for a
functional PR complex as well as the order and stoichiometry of
their assembly.29 Heat shock protein 90 (HSP90) is a molecular
chaperone involved in many cellular processes and is a key
component in PR complexes. In addition to stabilizing PR in
the cytoplasm, HSP90 potentiates PR’s hormone-dependent
response by binding to its LBD, causing it to adopt an open
conformation that allows the hormone to enter and bind.30
This process is ATP-dependent31 and was demonstrated in
binding assays to be inhibited by geldanamycin,32 a specific
inhibitor of HSP90 ATPase domain. Therefore, we first tested
whether 17-AAG (17-N-allylamino-17-demethoxygeldanamy-
cin), a less toxic synthetic derivative of geldanamycin, interferes
with RU486-BODIPY nuclear accumulation. Indeed, in T47D
cells treated with 17-AAG for one hour prior to RU486-
BODIPY application, nuclear fluorescence accumulation was
inhibited in a dose-dependent manner (Figure 3a,b). The half-
maximal effective concentration (EC50) of 17-AAG for PR
nuclear translocation inhibition in this experimental setting was
Figure 2. RU486-BODIPY nuclear accumulation is PR dependent. (a)
RU486-BODIPY accumulates in the nuclei of PR positive cells but not
PR negative cells. T47D (PR positive) or MDA-MB-231 (PR
negative) cells were incubated with 5 nM RU486-BODIPY for 15
min, washed, and imaged after 45 min. (b) Nuclear accumulation of
RU486-TAMRA in T47D cells can be competed off with PR agonist
but not with GR agonist. T47D cells were coincubated with 5 nM
RU486-BODIPY and 100 nM progesterone (PR agonist) or
dexamethasone (GR agonist) for 15 min, washed, and imaged after
45 min. Scale bar 20 μm.
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76 ± 11 nM, much lower than its reported IC50 in T47D cells
(3.82 ± 0.97 μM upon 24 h treatment33). Inhibition of histone
deacetylases (HDAC) by broad spectrum inhibitors such as
vorinostat (SAHA) and panobinostat (LBH-589), which leads
to HSP90 hyper-acetylation and dysfunction,34 also resulted in
a marked decrease of nuclear fluorescence accumulation
(Figure 3c and SI Figure S11). Together, these results reinforce
the importance of a functional HSP90 to PR translocation and
demonstrate that RU486-BODIPY is effective in sensing
perturbations to this process. HSP70 is another chaperone
involved in the early steps of PR complex assembly.35
VER155008, a recently reported specific HSP70 inhibitor,36
failed to disrupt PR translocation even after 12 h of treatment.
On the other hand, methylene blue, also reported to inhibit
HSP70,37 significantly decreased the rate of PR translocation.
However, methylene blue is not HSP70-specific; hence its effect
on PR cannot be solely attributed to HSP70 inhibition.
FKBP52 (FK506-binding protein 4) is an immunophilin
thought to act in steroid-receptor complexes, including PR, as
an adapter to the motor protein dynein to facilitate receptor
shuttling along cytoskeletal tracks.38 Inhibition of FKBP52
PPIase activity (peptidylprolyl isomerase) by FK506 has been
demonstrated to block PR hormone-dependent transcription
activation.39 We therefore tested the effect of FKBP52-dynein
inhibition on PR trafficking. Pretreatment of T47D cells with
FK506 (10 μM, 12 h) had no effect on RU486-BODIPY
nuclear accumulation. In addition, inhibition of dynein by
erythro-9-amino-β-hexyl-α-methyl-9H-purine-9-ethanol
(EHNA, 500 μM, 1 h) also failed to affect PR translocation. In
combination, while these observations do not rule out PR
trafficking along cytoskeletal tracks, they imply that nuclear
translocation does not exclusively rely on active cytoskeletal
transport and highlight the need to clarify the role of active
movement machinery in PR complex shuttling. In addition,
they also suggest that the requirement for FKBP52 activity in
PR transcriptional activity is downstream of the nuclear
translocation process.
Finally, we tested whether RU486-BODIPY will accumulate
preferentially in tissues that naturally express high levels of
progesterone receptor in vivo.40 We first evaluated the
detectable dose by intravenous injection of either 1 or 10
nmol RU-486-BODIPY into FBV/N female mice (one mouse
each) and analyzing tissue uptake by HPLC/MS/MS 4 h
postinjection. While the lower dose was hardly detectable in
any tissue (data not shown), at the higher dose, RU486-
BODIPY was detected in most analyzed tissues. Therefore, we
used the high-dose conditions (10 nmol) to similarly treat and
analyze three more mice (Figure 3d). At 4 h post injection, no
probe was detected in the blood or the brain. Although RU486
has a very long half-life in human, in rodents it is considerably
reduced (30 vs 1 h, respectively).41 The highest uptake of
RU486-BODIPY was observed in the liver, suggestive of its role
in metabolism and excretion of the probe, and also in
accordance with RU486 biodistribution in rodents.41 Impor-
tantly, RU486 BODIPY accumulation in uterus was consis-
tently and significantly higher than in muscle (∼3.5-fold on
average). The ovaries also showed a consistently higher uptake
than muscle (∼1.2-fold), but this difference was not statistically
significant.
In conclusion, we have designed and synthesized two
fluorescent ligands for the human progesterone receptor. The
ligands show antagonistic potency comparable to their parent
Figure 3. Effect of PR-multiprotein-complex modulators on RU486-BODIPY mediated PR nuclear translocation. (a) Dose−response curve of PR
nuclear translocation in T47D cells treated with HSP90 inhibitor 17-AAG. Cells were incubated with 17-AAG at indicated concentrations for 1 h
before treated with 5 nM RU486-BODIPY. Each data point represents mean nuclear (●) or cytoplasmic (▲) fluorescence intensity of 30 cells. Error
bars represent ± SD. (b) Effect of 17-AAG on PR nuclear translocation at 0.1 and 10 μM. Scale bar 20 μm. (c) Cellular distribution of 5 nM RU486-
BODIPY in T47D cells pretreated with: 0.1% v/v DMSO for 12 h (control), 10 μM 17-AAG or 500 μM EHNA for 1 h, 10 μM FK506 for 2 h, 10
μM vorinostat, panobinostat, VER-155008, or methylene blue for 12 h. Each bar represents the ratio of mean nucleus-to-cytoplasm fluorescence of
30 cells. Error bars represent ± SD. * p < 0.01 (two-tail t-test). (d) Tissue distribution of RU486-BODIPY in FVB/N female mice 4 h post I.V.
injection (n = 4). Error bars represent ± SD. * p < 0.05 (one-tail t-test).
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RU486 in live cells and have spectroscopic properties suitable
for fluorescence imaging. Both ligands triggered PR nuclear
translocation in a receptor-dependent and specific manner in
endogenously expressing cells. RU486-BODIPY was used to
study the effect of PR complex components inhibition on its
nuclear translocation process. Our results reinforce the
importance of functional HSP90 in this process as both
inhibition of its ATPase activity and its hyperacetylation, led to
impaired PR shuttling. In addition, we found that FKBP52
activity is not essential for PR nuclear translocation, suggesting
that FKBP52 plays a role in PR activation after the nuclear
accumulation process. Finally, RU486-BODIPY preferentially
accumulated in tissues that express high levels of PR in vivo.
Thus, RU486-BODIPY’s design and properties make it a
potential candidate for in vivo imaging of PR by PET through
incorporation of 18F into the BODIPY fragment. Noninvasive
whole-body imaging of steroid receptors could be of
considerable value in classifying and staging many cancers of
the endocrine and reproductive systems.
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